"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC

被引：0
|
作者：
Zheng, Mei-Mei [1 ,2 ]
Wu, Yi-Long [1 ]
机构：
[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 06 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
[2] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 08期
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; GEFITINIB;
D O I：
10.1016/j.jtho.2024.04.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1146 / 1150
页数：5
相关论文
共 50 条
  • [1] "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC
    Makarem, Maisam
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (08) : 1151 - 1154
  • [2] Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy
    Mascia, Francesca
    Lam, Gary
    Keith, Christopher
    Garber, Caroline
    Steinberg, Seth M.
    Kohn, Elise
    Yuspa, Stuart H.
    SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (199)
  • [3] Gold nanorod immunoassay to quantify C-Met expression in NSCLC patients selected for anti-EGFR therapy
    Caldwell, Chuck
    Kannan, Raghuraman
    Arthur, Gerald
    Shin, Dmitry
    Ersoy, Ilker
    Hammer, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S18 - S18
  • [4] Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
    Yoojoo Lim
    Sheehyun Kim
    Jun-Kyu Kang
    Hwang-Phill Kim
    Hoon Jang
    Hyojun Han
    Hyoki Kim
    Min Jung Kim
    Kyung-Hun Lee
    Seung-Bum Ryoo
    Ji Won Park
    Seung-Yong Jeong
    Kyu Joo Park
    Gyeong Hoon Kang
    Sae-Won Han
    Tae-You Kim
    Scientific Reports, 11
  • [5] Re-visiting EGFR amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers.
    Kato, Shumei
    Okamura, Ryosuke
    Mareboina, Manvita
    Lee, Suzanna
    Goodman, Aaron
    Patel, Sandip Pravin
    Fanta, Paul T.
    Schwab, Richard B.
    Sicklick, Jason K.
    Raymond, Victoria M.
    Lanman, Richard B.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
    Lim, Yoojoo
    Kim, Sheehyun
    Kang, Jun-Kyu
    Kim, Hwang-Phill
    Jang, Hoon
    Han, Hyojun
    Kim, Hyoki
    Kim, Min Jung
    Lee, Kyung-Hun
    Ryoo, Seung-Bum
    Park, Ji Won
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Han, Sae-Won
    Kim, Tae-You
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
    Kato, Shumei
    Okamura, Ryosuke
    Mareboina, Manvita
    Lee, Suzanna
    Goodman, Aaron
    Patel, Sandip P.
    Fanta, Paul T.
    Schwab, Richard B.
    Vu, Peter
    Raymond, Victoria M.
    Lanman, Richard B.
    Sicklick, Jason K.
    Lippman, Scott M.
    Kurzrock, Razelle
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 14
  • [8] Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
    Apter, L.
    Moser, S. Sharman
    Wollner, M.
    Chodick, G.
    Siegelmann-Danieli, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S405 - S405
  • [9] The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression-free survival in patients with advanced EGFR-mutated NSCLC
    Han, Jie
    Xu, Yan
    Zhou, Yumei
    Yang, Aiju
    Cui, Jianfeng
    Chen, Pengxiang
    Zhao, Hongyu
    Zhou, Xingqin
    Shen, Chaoyan
    Yu, Jinming
    Lu, Heng
    ONCOLOGY LETTERS, 2020, 20 (01) : 391 - 400
  • [10] Association of bevacizumab-free interval with efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer.
    Komori, Azusa
    Taniguchi, Hiroya
    Narita, Yukiya
    Uegaki, Shiori
    Nitta, Sohhei
    Yamaguchi, Kazuhisa
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345